Skip to main content
KAZIA THERAPEUTICS LTD logo

KAZIA THERAPEUTICS LTD — Investor Relations & Filings

Ticker · KZIA ISIN · US48669G1058 US Professional, scientific and technical activities
Open in API
Filings indexed 1,045 across all filing types
Latest filing 2025-12-23 Regulatory Filings
Country US United States of America
Listing US KZIA

About KAZIA THERAPEUTICS LTD

https://www.kaziatherapeutics.com/

Kazia Therapeutics Ltd. is an oncology-focused biotechnology company engaged in the development of innovative drugs for cancer. The company's lead program is paxalisib, a small molecule inhibitor of the PI3K/AKT/mTOR pathway designed to cross the blood-brain barrier, which is being investigated for various forms of brain cancer. Its development pipeline also includes EVT801, a selective VEGFR3 inhibitor being studied for its potential to block the growth of blood and lymphatic vessels that support tumor growth. The company focuses on addressing cancers with high unmet medical needs through its portfolio of targeted therapies.

Recent filings

Filing Released Lang Actions
Regulatory Filings 2025
Regulatory Filings
2025-12-23 English
POS AM
Capital/Financing Update Classification · 95% confidence The document is a Post-Effective Amendment No. 1 to a Form F-1 Registration Statement filed with the SEC, related to the Securities Act of 1933. It includes detailed information about the registration of American Depositary Shares (ADSs) for resale by a selling shareholder. The document references the inclusion of audited consolidated financial statements from the registrant's Annual Report on Form 20-F for the fiscal year ended June 30, 2025, but the document itself is a registration statement amendment primarily focused on securities registration and resale, not a financial report or earnings release. The document is lengthy (15,000 characters) and contains detailed legal and offering information typical of a capital raising or securities registration filing. Therefore, it fits best under the category of Capital/Financing Update (CAP), which covers updates on company fundraising, financing activities, or capital structure changes, including registration statements and amendments related to securities offerings.
2025-12-19 English
POS AM
Capital/Financing Update Classification · 95% confidence The document is a Post-Effective Amendment No. 2 to a Form F-1 Registration Statement filed with the SEC, related to the Securities Act of 1933. It includes updates such as audited consolidated financial statements from the registrant's Annual Report on Form 20-F for the fiscal year ended June 30, 2025. The document is a registration statement amendment primarily concerning securities registration and resale by selling shareholders. It is not a financial report like an Annual Report (10-K) or an Earnings Release, nor is it a proxy, governance, or management report. The document is a formal SEC filing related to capital markets and securities registration, which fits the category of Capital/Financing Update (CAP). The length and content confirm it is a substantive filing, not a brief announcement or certification. Therefore, the best classification is CAP with high confidence.
2025-12-19 English
F-1/A
Regulatory Filings Classification · 95% confidence The document is titled as an Amendment No. 1 to Form F-1 Registration Statement filed with the SEC under the Securities Act of 1933. It is a registration statement for securities offering, specifically for American Depositary Shares (ADSs) of Kazia Therapeutics Limited. The text includes detailed information about the offering, selling shareholders, risk factors, use of proceeds, dividend policy, capitalization, share descriptions, plan of distribution, legal matters, and other related information typical of a registration statement prospectus. It is not a financial report, earnings release, or management discussion. It is a regulatory filing related to securities registration and offering. Therefore, the appropriate classification is Regulatory Filings (RNS). The document length is substantial (15,000 characters), and it is not merely an announcement of a report but the actual registration statement document.
2025-12-19 English
F-1
Capital/Financing Update Classification · 95% confidence The document is a Form F-1 Registration Statement filed with the U.S. Securities and Exchange Commission (SEC) under the Securities Act of 1933. It is a registration statement for the resale of American Depositary Shares by selling shareholders. The document includes a preliminary prospectus, details about the offering, selling shareholders, use of proceeds, risk factors, and other information typical of a registration statement for securities offerings. It is not an annual report, earnings release, or any other type of financial report. It is a capital markets filing related to the registration of securities for sale to the public. Therefore, the appropriate classification is Capital/Financing Update (CAP). The document length is substantial (15,000 characters), and it contains detailed offering information, not just an announcement or a brief notice, so it is not a Report Publication Announcement or Regulatory Filing. Confidence is high given the clear identification of the form and content.
2025-12-19 English
6-K
Regulatory Filings Classification · 95% confidence The document is a Form 6-K filed by a foreign private issuer, Kazia Therapeutics Limited, reporting on Nasdaq listing compliance issues and the resolution thereof. It is a regulatory update about the company's listing status and compliance with Nasdaq rules, including the cancellation of a hearing due to regained compliance. The document is short (2565 characters) and does not contain financial statements or detailed financial analysis. It is not an annual or quarterly report, nor an earnings release or management discussion. It is a regulatory filing providing an update on listing compliance and related correspondence with Nasdaq. Therefore, it fits best under Regulatory Filings (RNS).
2025-12-19 English

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.